Rep. Bruce Westerman Purchases Shares of Pfizer Inc. (NYSE:PFE)

Representative Bruce Westerman (R-Arkansas) recently bought shares of Pfizer Inc. NYSE: PFE. In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Pfizer stock on March 3rd. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of LVMH Moët Hennessy - Louis Vuitton, Société Européenne OTCMKTS: LVMUY on 4/2/2025.
• Purchased $1,001 - $15,000 in shares of Sony Group NYSE: SONY on 3/24/2025.
• Purchased $1,001 - $15,000 in shares of Mitsubishi UFJ Financial Group NYSE: MUFG on 3/21/2025.
• Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 3/21/2025.
• Sold $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Medtronic NYSE: MDT on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 3/20/2025.

Pfizer Stock Up 1.7 %

Shares of PFE stock traded up $0.38 during trading hours on Tuesday, reaching $22.42. The company had a trading volume of 8,021,774 shares, compared to its average volume of 40,326,628. The company has a market cap of $127.14 billion, a price-to-earnings ratio of 15.92, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The business has a fifty day simple moving average of $24.81 and a 200-day simple moving average of $26.11. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the firm earned $0.10 earnings per share. The firm's revenue was up 24.7% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on PFE shares. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday. They set a "neutral" rating and a $24.00 price target for the company. Finally, UBS Group dropped their price objective on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $29.57.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently bought and sold shares of PFE. Passumpsic Savings Bank grew its stake in shares of Pfizer by 8.4% in the third quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock worth $743,000 after purchasing an additional 1,998 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Pfizer in the 3rd quarter valued at approximately $1,499,000. Westside Investment Management Inc. boosted its position in shares of Pfizer by 7.7% during the third quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock valued at $404,000 after purchasing an additional 1,004 shares in the last quarter. Diamant Asset Management Inc. raised its holdings in Pfizer by 8.4% in the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock worth $246,000 after purchasing an additional 660 shares in the last quarter. Finally, Morse Asset Management Inc bought a new stake in shares of Pfizer during the 3rd quarter valued at $2,649,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by insiders.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.